Value and Limitations of Calcium Channel Blockade In the Treatment of Pulmonary Hypertension Associated with CREST - Case Reports

Pressly, Thomas A.; Winkler, Anne; Alpert, Martin A.; Jackson, Robert W.; Mukerji, Vaskar; Benge, J. Michael; Sharp, Gordon C.
April 1988
Angiology;Apr1988, Vol. 39 Issue 4, p385
Academic Journal
Reversible vasospasm has been hypothesized to underlie the development of pulmonary hypertension in patients with CREST. Drugs that prevent arterial spasm have been used to treat pulmonary hypertension with variable results. The disparate pulmonary hemodynamic responses to calcium channel blockade reported herein suggest that CREST patients with mild pulmonary hypertension may have a component of reversible vasospasm responsive to vasodilator therapy, whereas patients with moderate to severe pulmonary hypertension may have fixed vessel lesions precluding a satisfactory response to calcium channel blockade.


Related Articles

  • Pulmonary Hypertension in Cardiac Surgery. Denault, Andr�; Deschamps, Alain; Tardif, Jean-Claude; Lambert, Jean; Perrault, Louis // Current Cardiology Reviews;2010, Vol. 6 Issue 1, p1 

    Pulmonary hypertension is an important prognostic factor in cardiac surgery associated with increased morbidity and mortality. With the aging population and the associated increase severity of illness, the prevalence of pulmonary hypertension in cardiac surgical patients will increase. In this...

  • Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Hallowell, Robert W.; Reed, Robert M.; Fraig, Mostafa; Horton, Maureen R.; Girgis, Reda E. // Pulmonary Circulation;2012, Vol. 2 Issue 1, p101 

    Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), particularly in idiopathic pulmonary fibrosis (IPF) and ILD associated with connective tissue disease, where the underlying pathology is often a nonspecific interstitial pneumonia (NSIP) pattern. The degree...

  • Comparison of pulmonary vascular function and structure in early and established hypoxic pulmonary hypertension in rats. Jeffery, Trina K; Wanstall, Janet C // Canadian Journal of Physiology & Pharmacology;Mar2001, Vol. 79 Issue 3, p227 

    In pulmonary hypertension, changes in pulmonary vascular structure and function contribute to the elevation in pulmonary artery pressure. The time-courses for changes in function, unlike structure, are not well characterised. Medial hypertrophy and neomuscularisation and reactivity to vasoactive...

  • Nutritional Assessment in Patients With Pulmonary Arterial Hypertension Facing Transplantation. Coplan, Beth; Studer, Sean // Advances in Pulmonary Hypertension;Summer2013, Vol. 12 Issue 2, p96 

    The article cites a research study that discusses the ideal diet for patients with pulmonary arterial hypertension facing transplantation. It is said that clinicians treating patients with pulmonary arterial hypertension (PAH) are very likely to encounter patients who are obese or underweight....

  • Recent Phase 3 Results. Levine, Deborah J.; Torres, Fernando // Advances in Pulmonary Hypertension;Summer2013, Vol. 12 Issue 2, p53 

    The article examines the PATENT-1 study results related to treatment of pulmonary hypertension (PH), and findings from CHEST-1, and outcomes of the SERAPHIN trial. It highlights results of treating patients with riociguat for pulmonary arterial hypertension (PAH). Also the treatment of chronic...

  • Continuous Intravenous Administration of a Low Dose of Epoprostenol Greatly Decreased Serum Concentrations of Endothelin-1 in Primary Pulmonary Hypertension. Kakinuma, Yoshihiko; Honma, Satoshi; Morimoto, Takashi; Maruyama, Hidekazu; Yamazaki, Akira; Ishimitsu, Toshiyuki; Yamaguchi, Iwao // Angiology;Sep/Oct2005, Vol. 56 Issue 5, p641 

    Endothelin-1 (ET-1) is known to be a principal factor in the pathogenesis of primary pulmonary hypertension (PPH). Recently intravenous administration of epoprosterol improved the survival rate in PPH. However, the effect of epoprosterol on ET-1 remains to be investigated. Therefore, we studied...

  • Expression of Human Herpesvirus 8 in Primary Pulmonary Hypertension. Cool, Carlyne D.; Rai, Pradeep R.; Yeager, Michael E.; Hernandez-Saavedra, Daniel; Serls, Amanda E.; Bull, Todd M.; Geraci, Mark W.; Brown, Kevin K.; Routes, John M.; Tuder, Rubin M.; Voelkel, Norbert F. // New England Journal of Medicine;9/18/2003, Vol. 349 Issue 12, p1113 

    Background: Severe pulmonary hypertension constitutes a group of diseases characterized by complex, lumen-occluding vascular lesions that develop in genetically susceptible persons. The only viral infection associated with severe pulmonary hypertension has been that due to human immunodeficiency...

  • Severe Mitral Regurgitation with a Normal- Sized Left Atrium. Gould, Lawrence; Reddy, C. V. Ramana // Angiology;Feb1978, Vol. 29 Issue 2, p174 

    The syndrome of severe mitral regurgitation with a normal-sized left atrium may or may not be associated with pulmonary hypertension and prominent left atrial V waves. To explain these pressure alterations by a single pressure-volume relationship is probably not adequate. It would appear that,...

  • Advances in Prostacyclin Therapy for Pulmonary Arterial Hypertension. Eells, Patricia L. // Critical Care Nurse;Apr2004, Vol. 24 Issue 2, p42 

    Focuses on the developments in pulmonary arterial hypertension (PAH) treatment as of April 2004. Description of PAH; Reclassification of pulmonary hypertension; Other forms of pulmonary hypertension as described in the World Health Organization proposals.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics